title: Coronary vasomotor response to phenylephrine in heart transplant patients.
abstract: BACKGROUND
  Coronary vasomotor responses to sympathetic stimulation vary with endothelial-layer integrity or presence of atherosclerosis. Our study objective was to assess the effects of phenylephrine-induced alpha-adrenergic stimulation on coronary vasomotion in heart transplant recipients with and without graft atherosclerosis.
  
  
  METHODS
  Intracoronary phenylephrine (alpha(1)-selective agonist) was injected in 6 control subjects, 9 recipients with angiographically normal coronary arteries and 8 recipients with mild or moderate atherosclerosis. Coronary flow velocity was measured using a Doppler guide-wire. The diameters of 3 epicardial segments of the left coronary artery and coronary blood flow and resistance were assessed at baseline, after infusion of increasing acetylcholine doses (10(-7) and 10(-6) mol/liter) and after phenylephrine (150- to 200-microg bolus). Systemic and coronary hemodynamic parameters were measured immediately after acetylcholine and 1, 3, 5, 7, 10 and 15 minutes after phenylephrine.
  
  
  RESULTS
  Phenylephrine induced similar significant increases in rate pressure product in the 3 groups. Acetylcholine induced epicardial vasodilation in controls and vasoconstriction in transplant recipients. Phenylephrine induced epicardial vasodilation in controls and in angiographically normal recipients; subsequent vasoconstriction occurred in this last group. In the recipients with angiographic abnormalities, sustained vasoconstriction occurred. At peak phenylephrine effect, coronary blood flow (CBF) increased significantly (p < 0.001 vs baseline) in all 3 groups. Coronary resistance decreased in the 3 groups but the decrease was smaller in the recipients with angiographic abnormalities (p < 0.05 vs controls).
  
  
  CONCLUSIONS
  In heart transplant patients, graft atherosclerosis unmasks the direct coronary vasoconstricting effects of pharmacologic alpha-adrenergic stimulation.
authors.affiliation: Fédération de Cardiologie, Institut National de la Santé et de la Recherche Médicale U400, Centre d'Investigation Clinique, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris XII, Créteil, France. eaptecar@club-internet.fr
authors.forename: Eduardo
authors.initials: E
authors.lastname: Aptecar
authors.forename: Philippe
authors.initials: P
authors.lastname: Le Corvoisier
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Teiger
authors.forename: Patrick
authors.initials: P
authors.lastname: Dupouy
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Vermes
authors.forename: Said
authors.initials: S
authors.lastname: Sediame
authors.forename: Luc
authors.initials: L
authors.lastname: Hittinger
authors.forename: Daniel
authors.initials: D
authors.lastname: Loisance
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Dubois-Rande
authors.forename: Olivier
authors.initials: O
authors.lastname: Montagne
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000328:Adult; D003324:Coronary Artery Disease / Q000503:physiopathology*; D003326:Coronary Circulation / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000503:physiopathology*; D005260:Female; D016027:Heart Transplantation; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010656:Phenylephrine / Q000494:pharmacology*; D011183:Postoperative Complications / Q000503:physiopathology*; D014661:Vasoconstriction / Q000187:drug effects*; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology; D014666:Vasomotor System / Q000187:drug effects*
chemical_list: D000316:Adrenergic alpha-Agonists; D014665:Vasodilator Agents; D010656:Phenylephrine; D000109:Acetylcholine